GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acurx Pharmaceuticals Inc (NAS:ACXP) » Definitions » Interest Coverage

Acurx Pharmaceuticals (Acurx Pharmaceuticals) Interest Coverage : No Debt (1) (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Acurx Pharmaceuticals Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Acurx Pharmaceuticals's Operating Income for the three months ended in Dec. 2023 was $-5.12 Mil. Acurx Pharmaceuticals's Interest Expense for the three months ended in Dec. 2023 was $0.00 Mil. Acurx Pharmaceuticals has no debt. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Acurx Pharmaceuticals Inc has no debt.

(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Acurx Pharmaceuticals's Interest Coverage or its related term are showing as below:

ACXP' s Interest Coverage Range Over the Past 10 Years
Min: No Debt   Med: No Debt   Max: No Debt
Current: No Debt


ACXP's Interest Coverage is ranked better than
99.41% of 340 companies
in the Biotechnology industry
Industry Median: 138.73 vs ACXP: No Debt

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Acurx Pharmaceuticals Interest Coverage Historical Data

The historical data trend for Acurx Pharmaceuticals's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Acurx Pharmaceuticals Interest Coverage Chart

Acurx Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Interest Coverage
No Debt N/A No Debt No Debt No Debt

Acurx Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only No Debt No Debt No Debt No Debt No Debt

Competitive Comparison of Acurx Pharmaceuticals's Interest Coverage

For the Biotechnology subindustry, Acurx Pharmaceuticals's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acurx Pharmaceuticals's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acurx Pharmaceuticals's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Acurx Pharmaceuticals's Interest Coverage falls into.



Acurx Pharmaceuticals Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Acurx Pharmaceuticals's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Acurx Pharmaceuticals's Interest Expense was $0.00 Mil. Its Operating Income was $-14.58 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Acurx Pharmaceuticals had no debt (1).

Acurx Pharmaceuticals's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Here, for the three months ended in Dec. 2023, Acurx Pharmaceuticals's Interest Expense was $0.00 Mil. Its Operating Income was $-5.12 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Acurx Pharmaceuticals had no debt (1).

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Acurx Pharmaceuticals  (NAS:ACXP) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Acurx Pharmaceuticals Interest Coverage Related Terms

Thank you for viewing the detailed overview of Acurx Pharmaceuticals's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Acurx Pharmaceuticals (Acurx Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
259 Liberty Avenue, Staten Island, NY, USA, 10305
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.
Executives
David P Luci director, 10 percent owner, officer: President and CEO
Robert J Deluccia director, 10 percent owner 40 WASHINGTON STREET, SUITE 220, WELLESLEY HILLS MA 02481
Carl Sailer director 4 GREENBRIAR LANE, MONTVALE NJ 07645
Thomas L Harrison director
Joseph C Scodari director JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Jack H Dean director C/O RESEARCH PHARMACEUTICAL SERVICES,INC, 520 VIRGINIA DRIVE, FORT WASHINGTON PA 19034
Robert G. Shawah officer: Chief Financial Officer C/O DIPEXIUM PHARMACEUTICALS, LLC, 74 BROAD STREET, NEW YORK NY 10004
James J. Donohue director C/O ACURX PHARMACEUTICALS, INC., 259 LIBERTY AVENUE, STATEN ISLAND NY 10305

Acurx Pharmaceuticals (Acurx Pharmaceuticals) Headlines

From GuruFocus